Clinical Trial Update: Beta-Lactam Containing Regimen for the Shortening of Buruli Ulcer Disease Therapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating whether a beta-lactam-containing regimen can shorten therapy for Buruli ulcer, and recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Buruli Ulcer

Drugs mentioned

• Beta-lactam containing regimen

Snippet

Sponsor: Fundacion Agencia Aragonesa para la Investigacion y Desarrollo (ARAID) | Conditions: Buruli Ulcer | Phase 2 | Status: RECRUITING